Academic Journals Database
Disseminating quality controlled scientific knowledge

Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence

ADD TO MY LIST
 
Author(s): Mistry Suresh | Trivedi Hiren | Parmar Dinesh | Dalvi Prashant | Jiyo Chacko

Journal: Indian Journal of Pharmacology
ISSN 0253-7613

Volume: 43;
Issue: 2;
Start page: 183;
Date: 2011;
Original page

Keywords: Clopidogrel | drug interaction | omeprazole | proton pump inhibitors

ABSTRACT
Clopidogrel is a prodrug which requires cytochrome P450 2C19 (CYP 2C19) enzyme for its conversion to an active thiol metabolite. Proton pump inhibitors (PPIs) inhibits enzyme CYP 2C19 interfering with the conversion of clopidogrel into its active metabolite. Studies document the possible interaction of clopidogrel and PPIs leading to a decrease in the antiplatelet efficacy of clopidogrel. A PubMed/MEDLINE database literature search was carried out and the bibliographies of found articles were checked for other relevant literature. Most retrospective cohort studies and studies using platelet markers found a significant association between PPI use especially omeprazole and decreased efficacy of clopidogrel while few comparative trials using clinical outcomes found no association between the same. Pantoprazole was not associated with the decrease in the antiplatelet efficacy of clopidogrel. Patients on dual antiplatelet therapy and/or with a history of gastrointestinal bleed will require gastroprotection in the form of PPIs. In such cases, pantoprazole should be the preferred PPI. Rabeprazole can be used as an alternative.
Why do you need a reservation system?      Affiliate Program